<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03258931</url>
  </required_header>
  <id_info>
    <org_study_id>ARO-021</org_study_id>
    <nct_id>NCT03258931</nct_id>
  </id_info>
  <brief_title>Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML</brief_title>
  <official_title>Phase III Randomized Study of Crenolanib Versus Midostaurin Administered Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed Subjects With FLT3 Mutated Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arog Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arog Pharmaceuticals, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase III randomized multi-center study designed to compare the efficacy of crenolanib with&#xD;
      that of midostaurin when administered following induction chemotherapy, consolidation&#xD;
      chemotherapy and bone marrow transplantation in newly diagnosed AML subjects with FLT3&#xD;
      mutation. About 510 subjects will be randomized in a 1:1 ratio to receive either crenolanib&#xD;
      in addition to standard first line treatment of AML (chemotherapy and if eligible,&#xD;
      transplantation) (arm A) or midostaurin and standard treatment (arm B). Potentially eligible&#xD;
      subjects will be registered and tested for the presence of FLT3 mutation. Once the FLT3&#xD;
      mutation status is confirmed and additional eligibility is established, subject will be&#xD;
      randomized and enter into the treatment phase.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 15, 2018</start_date>
  <completion_date type="Anticipated">November 2024</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival (EFS)</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>7 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse free survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite complete remission rate</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">510</enrollment>
  <condition>Newly Diagnosed FLT3 Mutated AML</condition>
  <arm_group>
    <arm_group_label>Crenolanib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Crenolanib following salvage chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Midostaurin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Midostaurin following salvage chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crenolanib</intervention_name>
    <description>Crenolanib will be administered orally</description>
    <arm_group_label>Crenolanib</arm_group_label>
    <other_name>Crenolanib besylate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midostaurin</intervention_name>
    <description>Midostaurin will be administered orally</description>
    <arm_group_label>Midostaurin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>100 mg/m² IV continuous infusion over 24 hours</description>
    <arm_group_label>Crenolanib</arm_group_label>
    <arm_group_label>Midostaurin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duanorubicin</intervention_name>
    <description>90 mg/m2 IV</description>
    <arm_group_label>Crenolanib</arm_group_label>
    <arm_group_label>Midostaurin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed diagnosis of de novo AML according to World Health Organization (WHO) 2016&#xD;
             classification&#xD;
&#xD;
          -  Presence of FLT3-ITD and/or D835 mutation(s) in bone marrow or peripheral blood&#xD;
&#xD;
          -  Age ≥ 18 years and ≤ 60 years&#xD;
&#xD;
          -  Adequate hepatic function within 48 hours prior to induction chemotherapy&#xD;
&#xD;
          -  Adequate renal functions within 48 hours prior to induction chemotherapy&#xD;
&#xD;
          -  ECOG performance status within 48 hours prior to induction chemotherapy ≤ 3&#xD;
&#xD;
          -  Eligible for intensive cytarabine/daunorubicin (7+3) chemotherapy specified&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute promyelocytic leukemia (APL)&#xD;
&#xD;
          -  Known clinically active central nervous system (CNS) leukemia&#xD;
&#xD;
          -  Severe liver disease&#xD;
&#xD;
          -  Active infections&#xD;
&#xD;
          -  Known, active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)&#xD;
&#xD;
          -  Known infection with human immunodeficiency virus (HIV)&#xD;
&#xD;
          -  Prior systemic anti-cancer treatment (e.g. chemotherapy, tyrosine kinase inhibitors,&#xD;
             immunotherapy, or investigational agents)(except for hydroxyurea and/or leukapheresis)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>General Contact</last_name>
    <phone>214-593-0500</phone>
    <email>info@arogpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chatchada Karanes, MD</last_name>
      <phone>626-218-2405</phone>
      <email>CKaranes@coh.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ronald Reagan UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caspian Oliai, MD</last_name>
      <phone>310-206-5756</phone>
      <email>COliai@mednet.ucla.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>US Davis Health</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Jonas, MD</last_name>
      <phone>800-282-3284</phone>
      <email>bajonas@ucdavis.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikolai Podoltsev, MD</last_name>
      <phone>203-737-7059</phone>
      <email>nikolai.podoltsev@yale.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kendra Sweet, MD</last_name>
      <phone>813-745-6841</phone>
      <email>Kendra.Sweet@moffitt.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rush Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Larson, MD</last_name>
      <phone>312-942-5978</phone>
      <email>melissa_larson@rush.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John G Quigley, MD</last_name>
      <phone>312-413-1300</phone>
      <email>seanq@uic.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongtao Liu, MD</last_name>
      <phone>773-834-0589</phone>
      <email>hliu2@medicine.bsd.uchicago.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46206-5149</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heiko Konig, MD</last_name>
      <phone>317-274-3590</phone>
      <email>hkonig@iupui.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Vigil-Gonzales, MD</last_name>
      <phone>319-356-1206</phone>
      <email>carlos-vigil@uiowa.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kansas</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sunil Abhyankar, MD</last_name>
      <phone>913-588-9281</phone>
      <email>sabhyankar@kumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amir Fathi, MD</last_name>
      <phone>617-724-1124</phone>
      <email>AFATHI@mgh.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deacnss Medical Center Oncology</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Malgorzata McMasters, MD</last_name>
      <phone>617-667-9920</phone>
      <email>mmcmaste@bidmc.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Insitute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard M Stone, MD</last_name>
      <phone>617-632-2214</phone>
      <email>Richard_Stone@dfci.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay Yang, MD</last_name>
      <phone>800-527-6266</phone>
      <email>yangj@karmanos.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yue Guo, MD</last_name>
      <phone>800-436-7936</phone>
      <email>YGUO1@hfhs.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erica Warlick, MD</last_name>
      <phone>612-625-5467</phone>
      <email>ewarlick@umn.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>John Theurer Cancer Center at Hackensack UMC</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamie Koprivnikar, MD</last_name>
      <phone>551-996-5900</phone>
      <email>Jamie.Koprivnikar@hackensackmeridian.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Athena Kritharis, MD</last_name>
      <phone>732-235-4439</phone>
      <email>athena.kritharis@rutgers.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aditi Shastri, MD</last_name>
      <phone>718-920-4826</phone>
      <email>ASHASTRI@montefiore.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Roswell PArk</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eunice S Wang, MD</last_name>
      <phone>716-845-3544</phone>
      <email>eunice.wang@roswellpark.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>New York University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammad Abdul Hay, MD</last_name>
      <phone>646-501-4818</phone>
      <email>Maher.Abdulhay@nyulangone.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029-6574</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Mascarenhas, MD</last_name>
      <phone>212-241-3417</phone>
      <email>John.mascarenhas@mssm.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Jurcic, MD</last_name>
      <phone>646-317-5077</phone>
      <email>jgj2110@cumc.columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pinkal Desai, MD</last_name>
      <phone>646-962-2700</phone>
      <email>pid9006@med.cornell.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aaron Goldberg, MD</last_name>
      <phone>212-639-2126</phone>
      <email>goldbera@mskcc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane Liesveld, MD</last_name>
      <phone>585-275-5295</phone>
      <email>jane_liesveld@urmc.rochester.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The UNC Lineberger Comprehensive Cancer Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joshua Zeidner, MD</last_name>
      <phone>919-966-4432</phone>
      <email>Joshua_Zeidner@med.unc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Health, Section on Hematology &amp; Oncology</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rupali Roy Bhave, MD</last_name>
      <phone>336-713-0864</phone>
      <email>rbhave@wakehealth.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elie Traer, MD</last_name>
      <phone>503-418-9614</phone>
      <email>traere@ohsu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Keng, MD</last_name>
      <phone>319-356-1206</phone>
      <email>MK2PV@hscmail.mcc.virginia.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>August 21, 2017</study_first_submitted>
  <study_first_submitted_qc>August 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 23, 2017</study_first_posted>
  <last_update_submitted>May 21, 2020</last_update_submitted>
  <last_update_submitted_qc>May 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Midostaurin</mesh_term>
    <mesh_term>Crenolanib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03258931
org study id: ARO-021
nct id: NCT03258931
lead sponsor: 
is fda regulated drug: Yes
is fda regulated device: No
A phase III randomized multi-center study designed to compare the efficacy of crenolanib with
      that of midostaurin when administered following induction chemotherapy, consolidation
      chemotherapy and bone marrow transplantation in newly diagnosed AML subjects with FLT3
      mutation. About 510 subjects will be randomized in a 1:1 ratio to receive either crenolanib
      in addition to standard first line treatment of AML (chemotherapy and if eligible,
      transplantation) (arm A) or midostaurin and standard treatment (arm B). Potentially eligible
      subjects will be registered and tested for the presence of FLT3 mutation. Once the FLT3
      mutation status is confirmed and additional eligibility is established, subject will be
      randomized and enter into the treatment phase.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Event-free survival (EFS)
time frame: 5 years
measure: Overall Survival
time frame: 7 years
measure: Relapse free survival
time frame: 5 years
measure: Composite complete remission rate
time frame: 5 years
measure: Duration of response
time frame: 5 years
arm group label: Crenolanib
arm group type: Experimental
description: Crenolanib following salvage chemotherapy
arm group label: Midostaurin
arm group type: Active Comparator
description: Midostaurin following salvage chemotherapy
intervention type: Drug
intervention name: Crenolanib
description: Crenolanib will be administered orally
arm group label: Crenolanib
other name: Crenolanib besylate
intervention type: Drug
intervention name: Midostaurin
description: Midostaurin will be administered orally
arm group label: Midostaurin
intervention type: Drug
intervention name: Cytarabine
description: 100 mg/m² IV continuous infusion over 24 hours
arm group label: Crenolanib
arm group label: Midostaurin
intervention type: Drug
intervention name: Duanorubicin
description: 90 mg/m2 IV
arm group label: Crenolanib
arm group label: Midostaurin
criteria: 
gender: All
minimum age: 18 Years
maximum age: 60 Years
healthy volunteers: No
last name: General Contact
phone: 214-593-0500
email: info@arogpharma.com
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
country: United States
responsible party type: Sponsor
mesh term: Cytarabine
mesh term: Midostaurin
mesh term: Crenolanib
sharing ipd: No